AttgeNO (private company)
See something wrong or missing? Let us know
Offices:Stockholm
Industry:
Biotech
Health services
Pharma
Business model:
B2B
AttgeNO is working on the development of new blood vessel-inducing drugs. Supernitro (PDNO) is a new patented drug candidate for the treatment of acute life threatening high blood pressure in the lung, which may occur in conjunction with cardiac surgery and fatal outcome.
Investors:
we tracked 2 investors
You need an account to access this feature. Log in or create one from here.
Do you have a question? Talk to us.
values in USD
Investments 3.44m
You need an account to access this feature. Log in or create one from here.
Do you have a question? Talk to us.
Belgium
Netherlands
Austria
Germany
Switzerland
Denmark
Estonia
Finland
Iceland
Latvia
Lithuania
Norway
France
Ireland
Italy
Portugal
Spain
United Kingdom